When the USPSTF recommended against prostate-specific antigen screening for prostate cancer in 2012, researchers began studying what effect this would have on diagnosing and treating prostate cancer.
UCLA Health experts are available to discuss a wide variety of topics of interest for the month of November.
When it comes to prostate cancer biopsies, risk and reality don’t always match up, according to research published online today in the Journal of Clinical Oncology. Investigators from SWOG, the cancer clinical trials network funded by the National Cancer Institute (NCI), found widespread detection bias after a fresh examination of data from the two largest prostate cancer prevention trials ever conducted in the United States.
A new study shows that Zika targets the male reproductive system, at least in mice. Three weeks after Zika infection, male mice had shrunken testicles, low levels of sex hormones and reduced fertility. The results suggest that Zika infection may interfere with men’s ability to have children.
The latest research and features in the fields of psychology and psychiatry.
Men can take birth control shots to prevent pregnancy in their female partners, according to a new study published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism.
Medical researchers at Indiana University Bloomington have found evidence for a link between prostate cancer, which affects millions of men aged 50 and older, and Ewing’s sarcoma, a rare form of cancer that affects children and young adults. The results of the study are reported in the journal Cell Reports.
A new report on Swedish men with non-aggressive prostate cancer suggests that a lot more American men could safely choose to monitor their disease instead of seeking immediate radiation treatment or surgery.
Study: Older men adhere closely to an idealized masculinity script that is incompatible with the realities of later life
Researchers studying reproductive science identified a network of proteins often linked to cancer as also important to male fertility and the birth of healthy offspring, according to a study in the Oct. 18 online issue of Cell Reports.
Among patients undergoing incisional hernia repair, the use of mesh to reinforce the repair was associated with a lower risk of hernia recurrence over 5 years compared with when mesh was not used, although with long-term follow-up, the benefits attributable to mesh were offset in part by mesh-related complications, according to a study published online by JAMA. The study is being released to coincide with its presentation at the American College of Surgeons Clinical Congress 2016.
Androgen Deprivation Therapy, a common hormone therapy to treat prostate cancer, may double a man’s risk of dementia, regardless of his age, Penn Medicine researchers reported.
Parental occupation and neighborhood income influence risks for getting melanoma, breast, cervical and prostate cancers, Huntsman Cancer Institute researchers report.
African-American and Hispanic men in the United States are less likely to receive therapy for prostate cancer compared to Caucasian men — even when they have more aggressive disease, according to new research from Roswell Park Cancer Institute and Vanderbilt University Medical Center. The study, senior authored by Willie Underwood, III, MD, MPH, MSci, of Roswell Park, has been published online ahead of print in the journal Urology.
Controversy over prostate cancer screening guidelines that discourage use of PSA tests did not significantly reduce use of the test, a five-year review of more than 275,000 visits at UT Southwestern Medical Center showed.
ROCHESTER, Minn. – A team of Mayo Clinic researchers has, for the first time, successfully mapped patterns of prostate cancer recurrence, following surgery. Using C-11 choline PET imaging and multiparametric MRI, researchers found an anatomically diverse pattern of recurrence, which may help optimize treatment of patients whose prostate cancer returns after surgery. The research findings are published today in the Journal of Urology.
A team of international researchers led by Associate Professor Gautam Sethi from the Department of Pharmacology at the Yong Loo Lin School of Medicine at the National University of Singapore has found that nimbolide, a bioactive terpenoid compound derived from Azadirachta indica or more commonly known as the neem plant, could reduce the size of prostate tumour by up to 70 per cent and suppress its spread or metastasis by half.
In a recent study, a Yale Cancer Center team determined that men who received hormonal therapy for prostate cancer had a net harm if they had a prior history of a heart attack.
While the association between alcohol and homicide may seem obvious, there has been no recent study of alcohol involvement in homicide victimization in U.S. states. This study drills down into the subject, looking at how often alcohol was involved in homicide victimization, and what socio-demographic and other factors may be predictors.
Seattle Cancer Care Alliance (SCCA) has opened a new Prostate Cancer Genetics Clinic at their South Lake Union campus in Seattle. The specialty clinic will serve patients with prostate cancer that has spread beyond the prostate (metastatic) and/or who have a family history of the disease or a family history of breast cancer, ovarian cancer, pancreatic cancer, lymphoma or leukemia. These men are more likely to have an inherited and more aggressive form of prostate cancer. Knowing a patient has a particular genetic mutation helps doctors choose the best treatment plan and can open doors for innovative clinical trials.
The underlying cause of male infertility is unknown for 30 percent of cases. In a pair of new studies, researchers at University of California San Diego School of Medicine determined that the reproductive homeobox (RHOX) family of transcription factors — regulatory proteins that activate some genes and inactivate others — drive the development of stem cells in the testes in mice. The investigators also linked RHOX gene mutations to male infertility in humans.
Low-risk prostate cancer patients may be able to undergo a shortened course of radiation therapy that cuts treatment by weeks and offers comparable outcomes and quality of life results as those who undergo longer treatment courses.
For men with intermediate risk prostate cancer, radiation treatment with brachytherapy alone can result in similar cancer control with fewer long-term side effects, when compared to more aggressive treatment that combines brachytherapy with external beam therapy (EBT), according to research presented today at the 58th Annual Meeting the American Society for Radiation Oncology (ASTRO).
For men with early stage, low-risk prostate cancer, treatment with hypofractionated radiation therapy (RT) offers comparable health-related quality of life outcomes in one-third less treatment time than conventional RT, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO).
What is the role of law and policy in eliminating racial health disparities? That is one of many topics to be discussed at “Black Men and Health Disparities,” an O’Neill Institute for National and Global Health Law Colloquium on Wednesday, Sept. 28.
A database study examining surgical removal of the prostate gland (radical prostatectomy) or a form of radiation therapy known as IMRT to treat prostate cancer that has spread to other parts of the body (metastatic) shows an association between each of these treatments and improved overall survival.
For men with intermediate risk prostate cancer, side effects at two years following radiation therapy (RT) were comparable for extremely-hypofractionated treatment, which was delivered in seven fractions across two and a half weeks, and conventional treatment of 39 fractions across eight weeks, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO).
In the largest study of its kind to date, researchers have identified and validated three distinct molecular subtypes of prostate cancer that correlate with distant metastasis-free survival and can assist in future research to determine how patients will respond to treatment, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO).
The prescription of testosterone supplementation for cardiovascular health, sexual function, physical function, mood, or cognitive function in men with “low T” is not supported by clinical trials data, conclude researchers who describe a review of more than 200 clinical trials published Sept. 21 in PLOS One.
While searching for a non-invasive way to detect prostate cancer cells circulating in blood, Duke Cancer Institute researchers have identified some blood markers associated with tumor resistance to two common hormone therapies.
In studies on rats, Johns Hopkins Medicine scientists report new evidence that the predominance of the hormone testosterone in males may explain why women are up to 10 times more likely than men to injure the anterior cruciate ligament (ACL) in their knees.
In light of the findings from the Prostate Testing for Cancer and Treatment (ProtecT) trial published today in the New England Journal of Medicine, the American Society for Radiation Oncology (ASTRO) would like to congratulate the authors and investigators for conceiving and completing a difficult clinical trial to randomize care for 2,664 men who volunteered to be a part of this study.
Most cancers have a sweet tooth but—mysteriously—some tumors prefer fat over sugar. Now, a study from Harvard Medical School reveals how these cancers develop their appetite for fat.
A clinical trial underway – known as the AMP study (for Antibody Meditated Prevention) – will determine whether infusing an experimental antibody (VRC01) into HIV-negative men and transgender individuals who have sex with men, will prevent the acquisition of HIV.
The world’s largest gathering of kidney health professionals will join forces in Chicago from November 15–20, 2016, to discuss research discoveries and how to move them from bench to bedside during the American Society of Nephrology’s Kidney Week 2016.
New research confirms that an innovative procedure combining MRI and ultrasound to create a 3D image of the prostate can more accurately locate suspicious areas and help diagnose whether it’s prostate cancer.
Men's hidden fears about body fat are fuelling gym attendance motivated by feelings of guilt and shame rather than a desire to build muscle, new research has shown.
Scientists at Cedars-Sinai have developed a new way to identify which prostate cancer patients are likely to develop aggressive types of the disease even if their tumors at first appear to be lower risk. The new findings could help physicians prescribe the most effective treatments for each patient based on how genes are activated in the individual tumor.
Loyola Medicine is the first center in the Midwest to offer the first effective PET/CT scan for prostate cancer patients. The scan can detect the location and extent of cancer that has recurred after initial treatment. Prostate PET/CT scans can detect cancer earlier than either CT scans alone or MRI scans.
The dreaded finger exam to check for prostate cancer used to be a mainstay of check-ups for older men. With its value now in question, some doctors share the risks and benefits with their patients and let them decide. So, should they or shouldn’t they? Research suggests that in most cases, it is time to abandon the test, says Wake Forest Baptist urologist Ryan Terlecki, M.D., “The evidence suggests that in most cases, it is time to abandon the digital rectal exam (DRE),” said Ryan Terlecki, M.D., a
Mount Sinai Experts are Making Strides in Prostate Cancer Treatment
The top causes of death among adult men in the United Sates are heart disease, stroke, cancer and chronic lower respiratory disease, according to the Mayo Clinic and the Centers for Disease Control (CDC). In a recent issue of Food Technology magazine published by the Institute of Food Technologists, contributing editor Linda Milo Ohr writes about some of the health concerns men have and the nutrients that may play beneficial roles in addressing them.
A novel MRI method that detects low levels of zinc ion can help distinguish healthy prostate tissue from cancer, UT Southwestern Medical Center radiologists have determined.
Research from investigators at Rutgers Cancer Institute of New Jersey; University of California, Los Angeles; University of California, Santa Cruz and other institutions shows a computational approach examining abnormal “signaling” in clinical prostate cancer tissues that is responsible for their spread and resistance to treatment and can help identify patient subsets for targeted therapies.
For the first time in Los Angeles County history, more Latinos than whites are being diagnosed with testicular cancer, a malady once regarded as a white man’s disease. This Q&A focuses on testicular cancer: who is at risk, why they are at risk and what preventive measures can be taken.
Prostate cancer researchers studying genetic variations have pinpointed 45 genes associated with disease development and progression.
Study maps out abnormal signaling pathways in prostate cancer cells and provides computational approaches to identify individualized targets for therapy
Sanford Burnham Prebys Medical Discovery Institute (SBP) has received a $1M donation from The Epstein Family Foundation for scientists to study pancreatic and prostate cancer. The gift, contributed by SBP board member Dan Epstein and his wife Phyllis, will support the lab of Nicholas Cosford, Ph.D., associate director of Translational Research at the Institute’s NCI-designated Cancer Center.
A study at Columbia University's Mailman School of Public Health showed that obesity was more prevalent in patients with a history of cancer than in the general population, and survivors of colorectal and breast cancers were particularly affected. The study is among the first to compare rates of obesity among U.S. cancer survivors and adults without a history of cancer. Findings are published online in the Journal of Clinical Oncology.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right